Press Release

Jul, 17 2024

Increasing Incidence Rate for Hypophosphatasia is driving the Growth of the Global Hypophosphatasia Treatment Market

The increasing incidence rate and epidemiology of Hypophosphatasia (HPP) are key drivers for market growth in treating this rare disease. This rising incidence means more people are seeking treatment options, spurring pharmaceutical companies to invest in research and development of new therapies. The market for HPP treatments is expanding rapidly as healthcare providers and patients alike recognize the need for effective interventions to improve quality of life and manage symptoms associated with this challenging condition.

Access Full Report @

Data Bridge Market Research analyzes that the Global Hypophosphatasia Treatment Market is expected to reach USD 1,812.12 million by 2031 from USD 1,329.26 million in 2023, growing at a CAGR of 4.4% in the forecast period of 2024 to 2031.

Key Findings of the Study

Hypophosphatasia Treatment Market

Favorable Reimbursement Policies

Favorable reimbursement policies play a crucial role in driving the availability and accessibility of treatments for Hypophosphatasia (HPP). When healthcare systems and insurance providers provide robust reimbursement for HPP therapies, it reduces financial barriers for patients and healthcare providers, facilitating broader access to these specialized treatments.

In countries where reimbursement policies are favorable, pharmaceutical companies are more incentivized to develop and commercialize HPP treatments. This can lead to a more competitive market with multiple treatment options, fostering innovation and improving treatment outcomes for patients. Moreover, favorable reimbursement policies encourage healthcare providers to prescribe these therapies confidently, knowing that patients can afford them without undue financial burden.

 Report Scope and Market Segmentation

Report Metric


Forecast Period

2024 to 2031

Base Year


Historic Year

2022 (Customizable to 2016–2021)

Quantitative Units

Revenue in USD Million

Segments Covered

Types (Odontohypophosphatasia, Pseudohypophosphatasia, and Others), Therapy Type (Enzyme Replacement Therapy and Supportive Therapy), Route of Administration (Injectable and Oral), End User (Hospitals, Speciality Clinics, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy)

Market Players Covered

AstraZeneca (U.K.), Pfizer Inc. (U.S.), Abbott (U.S.), Novartis AG (Switzerland), Be Biopharma (U.S.), PuREC (Japan), Rallybio (U.S.), Rampart Bioscience, Inc. (U.S.), AM-Pharma B.V.(Netherlands), and Roivant Sciences Ltd. (U.S.) among others

Data Points Covered in the Report

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework

Segment Analysis

The global hypophosphatasia treatment market is segmented into five notable segments based on types, therapy type, route of administration, end user, and distribution channel.

  • On the basis of types, the global hypophosphatasia treatment market is segmented into odontohypophosphatasia, pseudohypophosphatasia, and others

In 2024, the odontohypophosphatasia segment is expected to dominate the Global Hypophosphatasia Treatment Market

In 2024, the odontohypophosphatasia segment is expected to dominate the market with a market share of 52.85% due to its higher frequency of diagnosis, the visible impact of dental symptoms that drive treatment demand, and the efficacy of targeted enzyme replacement therapies that significantly improve patient outcomes.

  • On the basis of therapy type, the global hypophosphatasia treatment market is segmented into enzyme replacement therapy and supportive therapy

In 2024, the enzyme replacement therapy segment is expected to dominate the Global Hypophosphatasia Treatment Market

In 2024, the enzyme replacement therapy segment is expected to dominate the market share of 90.36% due to its proven efficacy in directly addressing the underlying enzyme deficiency, significantly improving patient outcomes and quality of life.

  • On the basis of route of administration, the global hypophosphatasia treatment market is segmented into injectable and oral. In 2024, the injectable segment is expected to dominate the market with a market share of 86.09%
  • On the basis of end user, the global hypophosphatasia treatment market is segmented hospitals, speciality clinics, and others. In 2024, the hospitals segment is expected to dominate the market with a market share of 69.98%
  • On the basis of distribution channel, the global hypophosphatasia treatment market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. In 2024, the hospital pharmacy segment is expected to dominate the market with a market share of 59.04%

Major Players

Data Bridge Market Research recognizes the following companies as the major market players in the global hypophosphatasia treatment market is AstraZeneca (U.K.), Pfizer Inc. (U.S.), Abbott (U.S.), Novartis AG (Switzerland).

Hypophosphatasia Treatment Market

Market Developments

  • In July 2021, AstraZeneca has finalized its acquisition of Alexion Pharmaceuticals, Inc., marking its entry into rare disease medicines. This move enhances AstraZeneca's scientific presence in immunology and allows for continued innovation in rare disease treatments, leveraging Alexion's complement-biology platform and pipeline. This acquisition represents a significant growth opportunity for AstraZeneca, addressing the unmet medical needs of patients with rare diseases
  •  In January 2024, AM-Pharma B.V. has initiated a Phase 2 clinical study, treating the first patients with ilofotase alfa to prevent cardiac surgery-associated renal damage (CSA-RD), a crucial step towards validating the compound's potential and advancing its development, ultimately benefiting the company by potentially expanding its therapeutic applications and market reach
  •  In October 2023, AM-Pharma B.V. has reported positive Phase 1b clinical results for ilofotase alfa as a potential enzyme replacement therapy in adult hypophosphatasia (HPP) patients. This milestone demonstrates the compound's efficacy and safety, potentially expanding its market and therapeutic applications, benefiting the company's growth and development
  • In May, CAMBRIDGE, Mass., Be Biopharma, Inc. (“Be Bio”), a company pioneering the discovery and development of Engineered B Cell Medicines (BCMs), presented results from new preclinical research demonstrating production of active ALP by a BCM, which highlights BCMs as a potential treatment for hypophosphatasia (HPP)
  •  In October 2021, a clinical trial utilizing PuREC's Rapid Expanding Cells for Hypophosphatase (HPP) Disease has commenced for the period of July 2021 – September 2022. This phase I/IIa trial for HPP treatment, conducted in partnership with Shimane University, marks the first human trial of its kind. Supported by funding from AMED (Japan Agency for Medical Research and Development), the study will assess the safety and efficacy of a novel treatment employing purified mesenchymal stem cells produced by PuREC, known as REC-01 cells
  •  In January 2024, Rallybio in collaboration with its partner Exscientia, remains focused on identifying a small molecule development candidate aimed at targeting ENPP1 for treating patients with hypophosphatasia (HPP). Substantial advancements have been achieved, and proof-of-mechanism studies are currently underway, conducted alongside a renowned global expert in HPP. Rallybio and Exscientia intend to share updates on the program's progress in the latter part of 2024
  •  In October 2023, Rampart Bioscience, Inc., a biotechnology company advancing next-generation biologics, has announced an $85 million Series A financing round. The funding will support the development of medicines designed to alleviate patients from disease burden and treatment challenges

Regional Analysis

Geographically, the countries covered in the global hypophosphatasia treatment market report are U.S., Canada, Mexico, Germany, U.K., France, Italy, Netherlands, Spain, Russia, Switzerland, Turkey, Belgium, rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Indonesia, Malaysia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, U.A.E., Israel, South Africa, Egypt, and rest of Middle East and Africa.

As per Data Bridge Market Research analysis:

North America is the dominant region in the Global Hypophosphatasia Treatment Market

North America is expected to dominate the market owing due to its early adoption of advanced therapies and robust healthcare infrastructure. North America will continue to dominate the market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the growing adoption of advanced technology in this region.

Asia-Pacific is estimated to be the fastest-growing region in the Global Hypophosphatasia Treatment Market

Asia-Pacific is expected to grow during the forecast period due to increasing awareness, improving healthcare infrastructure, and rising patient population. In addition, the rising level of healthcare expenditure and increasing per-capita income are expected to propel the market growth in this region.

For more detailed information about Global Hypophosphatasia Treatment Market click here –

Client Testimonials